Fig. 6: In vivo biodistribution and tumor inhibition of 4WJ-X-24 PTXs nanoparticles.
a Representative organ images showing specific tumor targeting of Alexa Fluor 647 labeled 4WJ-X-EGFRapt nanoparticles 8 h post-injection into mice bearing MDA-MB-231 xenograft (T: tumor, H: heart, S: spleen, L: lung, K: kidney, and Li: liver; Color scale: radiant efficiency, [p s−1 cm−2 sr−1] [μW cm−2]−1). Very low radiant mark was revealed in the liver of 4WJ-X-EGFRapt treated sample. b Quantitative analysis of biodistribution in tumors and normal organs, quantified from the organ images. c Intravenous treatment of nude mice bearing orthotopic MDA-MB-231 xenografts with 4WJ-X-24 PTXs-EGFRapt nanoparticles (purple) and control groups (turquoise: 4WJ-X-24 PTXs, red: PTX, blue: PBS) every other day for a total of five injections (8 mg kg−1, PTX per body weight, indicated by arrows). Mice body weight was monitored during the time course of treatments (n = 5 biologically independent animals, statistics was calculated by two-tailed unpaired t-test presented as mean ± SD, *p < 0.05, **p < 0.01, ****p < 0.0001; p = 0.038, 9.99 × 10−4, and 6 × 10−6 comparing 4WJ-X-24 PTXs-EGFRapt to PTX, 4WJ-X-24 PTXs, and PBS, respectively). d Representative images of breast cancer tumors harvested from mice after treatments (n = 5 biologically independent animals, statistics was calculated by two-tailed unpaired t-test presented as mean ± SD, *p < 0.05, ****p < 0.0001; p = 0.033 and 2.2 × 10−5 comparing 4WJ-X-24 PTXs-EGFRapt to 4WJ-X-24 PTXs, and PBS, respectively). Source data are provided as a Source Data file.
